Skip to main content
. 2021 Apr 7;113(11):1561–1569. doi: 10.1093/jnci/djab069

Figure 4.

Figure 4.

Kaplan-Meier estimates of overall survival according to the presence of EGFR amplification in the subgroup of patients with RAS/BRAF wild-type mCRC treated with anti-EGFR agents (n = 465). Blue lines indicate patients with EGFR-nonamplified mCRC (n = 431), whereas violet lines indicate patients with EGFR-amplified mCRC (n = 34). Patients with EGFR-amplified mCRC showed a better overall survival compared with patients with EGFR nonamplified mCRC. P values were calculated by means of the likelihood ratio test, 2-sided, in a Cox univariable regression model. CI = confidence interval; HR = hazard ratio; mCRC = metastatic colorectal cancer; OS = overall survival.